Sensitivity (95% CI) | Specificity (95% CI) | Exact agreement (95% CI) | Kappa (95% CI) | |
---|---|---|---|---|
Chemotherapy | 88.6% (84.2–91.9%) | 95.2% (92.9–96.8%) | 92.8% (90.8–95.0%) | 0.84 (0.80–0.88) |
Endocrine therapy | 88.1% (84.7–90.9%) | 94.2% (91.0–97.0%) | 90.7% (88.4–92.6%) | 0.81 (0.77–0.85) |
Anti-HER2 therapy | 73.7% (49.0–91.0%) | 99.2% (98.2–99.6%) | 98.5% (97.4–99.2%) | 0.71 (0.55–0.87) |
Radiotherapy | 94.7% (92.6–96.2%) | 88.5% (82.0–92.6%) | 93.4% (91.4–95.0%) | 0.81 (0.76–0.86) |